RT Journal Article
SR Electronic
T1 The role of SGLT-2 inhibitors in managing type 2 diabetes
JF Cleveland Clinic Journal of Medicine
JO Cleve Clin J Med
FD Cleveland Clinic
SP 47
OP 58
DO 10.3949/ccjm.88a.20088
VO 88
IS 1
A1 Yumiko Tsushima
A1 M. Cecilia Lansang
A1 Vinni Makin
YR 2021
UL http://www.ccjm.org/content/88/1/47.abstract
AB Sodium-glucose cotransporter-2 (SGLT-2) inhibitors are an exceptionally versatile class of medication, and their glycemic and nonglycemic benefits could help millions of patients with type 2 diabetes. Of note, they have been shown to improve cardiac and renal outcomes, much-needed benefits in patients with type 2 diabetes, who are at a higher risk for developing cardiac and renal dysfunction than those who do not have diabetes. The indications for SGLT-2 inhibitors may continue to expand as ongoing clinical trials provide more insight into these drugs.